Additionally, serum prostate-specific antigen (PSA) levels, a widely used biomarker for prostate cancer detection and monitoring, and body mass index (BMI) have been explored as potential modifiers of GSU risk. The gene discussed is KLK3; the disease is prostate carcinoma.